Back to search results

Exenatide for Gestational Diabetes

This study is looking at how the drug exenatide works in pregnant women with gestational diabetes. Exenatide is already approved to lower blood sugar in non-pregnant people with type 2 diabetes. Researchers want to understand how your body handles exenatide (pharmacokinetics) and how well exenatide helps your body control blood sugar and produce insulin (pharmacodynamics). This is important because current treatments for gestational diabetes don't always work well for everyone. You may be able to join if you are a pregnant woman between 18 and 50 years old with gestational diabetes that doesn't require other medical treatment. The study will measure how your blood sugar levels change over one week after taking exenatide. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 13 women. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your blood sugar levels will be measured at baseline and one week later.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05482789

Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

Recruiting
PHASE4Ages 18–50InterventionalTreatment
Maisa N. Feghali, MD
~13 participants
Updated 2026-04-20 on ClinicalTrials.gov
What's tested:Exenatide

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Area Under the Plasma Concentration Versus Time Curve (AUC) of glucose
Measured over Baseline and 1 week later

Conditions

Gestational Diabetes

Explore related trials

Gestational Diabetes

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Maisa Feghali, MD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh

Who to contact

Maisa Feghali, MD
[email protected]
412 647 1000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Pregnant women (singleton)
Gestational diabetes not requiring medical therapy
Between 18 and 50 years of age
Able to give written informed consent

Exclusion

Women in the first trimester of pregnancy
Hematocrit less than 30%
Current or past treatment with any hypoglycemic agent
Women with gastrointestinal disease or symptoms consistent with nausea, vomiting, abdominal pain or reflux requiring medical treatment.
Women with high triglyceride levels, history of gallbladder or pancreatic disease.
Clinical diagnosis or history of any renal insufficiency (or decreased creatinine clearance)

What this trial measures

  • Area Under the Plasma Concentration Versus Time Curve (AUC) of glucoseBaseline and 1 week later

    Glucose concentration over the course of each study visit following mixed tolerance test